CROSS COUNTRY HEALTHCARE INC (CCRN) Fundamental Analysis & Valuation
NASDAQ:CCRN • US2274831047
Current stock price
10.17 USD
-0.03 (-0.29%)
Last:
This CCRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CCRN Profitability Analysis
1.1 Basic Checks
- In the past year CCRN was profitable.
- In the past year CCRN had a positive cash flow from operations.
- In multiple years CCRN reported negative net income over the last 5 years.
- CCRN had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- CCRN has a Return On Assets of -21.13%. This is amonst the worse of the industry: CCRN underperforms 80.00% of its industry peers.
- CCRN has a Return On Equity of -29.38%. This is in the lower half of the industry: CCRN underperforms 68.00% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 0.54%, CCRN is doing worse than 63.00% of the companies in the same industry.
- CCRN had an Average Return On Invested Capital over the past 3 years of 6.06%. This is below the industry average of 8.40%.
- The last Return On Invested Capital (0.54%) for CCRN is well below the 3 year average (6.06%), which needs to be investigated, but indicates that CCRN had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.13% | ||
| ROE | -29.38% | ||
| ROIC | 0.54% |
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)6.06%
ROIC(5y)14.51%
1.3 Margins
- CCRN has a worse Operating Margin (0.24%) than 63.00% of its industry peers.
- CCRN's Operating Margin has declined in the last couple of years.
- CCRN has a Gross Margin (20.26%) which is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of CCRN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.24% | ||
| PM (TTM) | N/A | ||
| GM | 20.26% |
OM growth 3Y-71.15%
OM growth 5Y-31.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
2. CCRN Health Analysis
2.1 Basic Checks
- CCRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, CCRN has less shares outstanding
- Compared to 5 years ago, CCRN has less shares outstanding
- There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 4.89 indicates that CCRN is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 4.89, CCRN belongs to the best of the industry, outperforming 86.00% of the companies in the same industry.
- CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.89 |
ROIC/WACC0.06
WACC8.99%
2.3 Liquidity
- A Current Ratio of 3.78 indicates that CCRN has no problem at all paying its short term obligations.
- CCRN has a Current ratio of 3.78. This is amongst the best in the industry. CCRN outperforms 88.00% of its industry peers.
- CCRN has a Quick Ratio of 3.78. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 3.78, CCRN belongs to the best of the industry, outperforming 91.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.78 | ||
| Quick Ratio | 3.78 |
3. CCRN Growth Analysis
3.1 Past
- The earnings per share for CCRN have decreased strongly by -95.56% in the last year.
- CCRN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -46.59% yearly.
- CCRN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.56%.
- CCRN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.74% yearly.
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
3.2 Future
- The Earnings Per Share is expected to grow by 122.11% on average over the next years. This is a very strong growth
- CCRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.14% yearly.
EPS Next Y455.34%
EPS Next 2Y271.84%
EPS Next 3Y175.5%
EPS Next 5Y122.11%
Revenue Next Year-8.87%
Revenue Next 2Y-2.17%
Revenue Next 3Y0.18%
Revenue Next 5Y2.14%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. CCRN Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 508.50, which means the current valuation is very expensive for CCRN.
- 60.00% of the companies in the same industry are cheaper than CCRN, based on the Price/Earnings ratio.
- Compared to an average S&P500 Price/Earnings ratio of 26.91, CCRN is valued quite expensively.
- CCRN is valuated quite expensively with a Price/Forward Earnings ratio of 91.57.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of CCRN indicates a slightly more expensive valuation: CCRN is more expensive than 61.00% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 21.99, CCRN is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 508.5 | ||
| Fwd PE | 91.57 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CCRN indicates a somewhat cheap valuation: CCRN is cheaper than 68.00% of the companies listed in the same industry.
- CCRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CCRN is cheaper than 88.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.17 | ||
| EV/EBITDA | 11.36 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- A more expensive valuation may be justified as CCRN's earnings are expected to grow with 175.50% in the coming years.
PEG (NY)1.12
PEG (5Y)N/A
EPS Next 2Y271.84%
EPS Next 3Y175.5%
5. CCRN Dividend Analysis
5.1 Amount
- CCRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CCRN Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:CCRN (4/29/2026, 10:45:30 AM)
10.17
-0.03 (-0.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Industry Strength49.69
Industry Growth87.58
Earnings (Last)03-04 2026-03-04/amc
Earnings (Next)05-07 2026-05-07/amc
Inst Owners83.99%
Inst Owner Change0.02%
Ins Owners7.09%
Ins Owner Change17.24%
Market Cap327.47M
Revenue(TTM)1.05B
Net Income(TTM)-94.85M
Analysts74.67
Price Target11.9 (17.01%)
Short Float %3.84%
Short Ratio2.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-157.94%
Min EPS beat(2)-296.08%
Max EPS beat(2)-19.79%
EPS beat(4)1
Avg EPS beat(4)-107.17%
Min EPS beat(4)-296.08%
Max EPS beat(4)5.59%
EPS beat(8)3
Avg EPS beat(8)-61.22%
EPS beat(12)6
Avg EPS beat(12)-39.22%
EPS beat(16)10
Avg EPS beat(16)-25.76%
Revenue beat(2)0
Avg Revenue beat(2)-9.09%
Min Revenue beat(2)-9.46%
Max Revenue beat(2)-8.72%
Revenue beat(4)0
Avg Revenue beat(4)-7.87%
Min Revenue beat(4)-9.46%
Max Revenue beat(4)-5.84%
Revenue beat(8)0
Avg Revenue beat(8)-4.22%
Revenue beat(12)2
Avg Revenue beat(12)-2.78%
Revenue beat(16)5
Avg Revenue beat(16)-1.59%
PT rev (1m)2.55%
PT rev (3m)1.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-388.87%
EPS NY rev (1m)13.77%
EPS NY rev (3m)-7.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.76%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-3.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 508.5 | ||
| Fwd PE | 91.57 | ||
| P/S | 0.31 | ||
| P/FCF | 8.17 | ||
| P/OCF | 6.79 | ||
| P/B | 1.01 | ||
| P/tB | 1.42 | ||
| EV/EBITDA | 11.36 |
EPS(TTM)0.02
EY0.2%
EPS(NY)0.11
Fwd EY1.09%
FCF(TTM)1.25
FCFY12.24%
OCF(TTM)1.5
OCFY14.73%
SpS32.74
BVpS10.03
TBVpS7.19
PEG (NY)1.12
PEG (5Y)N/A
Graham Number2.12403 (-79.11%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.13% | ||
| ROE | -29.38% | ||
| ROCE | 0.68% | ||
| ROIC | 0.54% | ||
| ROICexc | 0.76% | ||
| ROICexgc | 1.17% | ||
| OM | 0.24% | ||
| PM (TTM) | N/A | ||
| GM | 20.26% | ||
| FCFM | 3.8% |
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)6.06%
ROIC(5y)14.51%
ROICexc(3y)6.35%
ROICexc(5y)14.73%
ROICexgc(3y)10.08%
ROICexgc(5y)21.91%
ROCE(3y)7.68%
ROCE(5y)18.37%
ROICexgc growth 3Y-70.95%
ROICexgc growth 5Y-31.89%
ROICexc growth 3Y-71.51%
ROICexc growth 5Y-28.12%
OM growth 3Y-71.15%
OM growth 5Y-31.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
F-Score6
Asset Turnover2.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 48.59% | ||
| Cap/Sales | 0.77% | ||
| Interest Coverage | 1.82 | ||
| Cash Conversion | 249.59% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.78 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 4.89 |
F-Score6
WACC8.99%
ROIC/WACC0.06
Cap/Depr(3y)57.55%
Cap/Depr(5y)63.04%
Cap/Sales(3y)0.7%
Cap/Sales(5y)0.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
EPS Next Y455.34%
EPS Next 2Y271.84%
EPS Next 3Y175.5%
EPS Next 5Y122.11%
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
Revenue Next Year-8.87%
Revenue Next 2Y-2.17%
Revenue Next 3Y0.18%
Revenue Next 5Y2.14%
EBIT growth 1Y103.69%
EBIT growth 3Y-79.18%
EBIT growth 5Y-28.09%
EBIT Next Year307.2%
EBIT Next 3Y80.75%
EBIT Next 5Y50.41%
FCF growth 1Y-64.01%
FCF growth 3Y-31.6%
FCF growth 5Y12.15%
OCF growth 1Y-59.83%
OCF growth 3Y-28.87%
OCF growth 5Y12.15%
CROSS COUNTRY HEALTHCARE INC / CCRN Fundamental Analysis FAQ
What is the ChartMill fundamental rating of CROSS COUNTRY HEALTHCARE INC (CCRN) stock?
ChartMill assigns a fundamental rating of 4 / 10 to CCRN.
What is the valuation status for CCRN stock?
ChartMill assigns a valuation rating of 4 / 10 to CROSS COUNTRY HEALTHCARE INC (CCRN). This can be considered as Fairly Valued.
What is the profitability of CCRN stock?
CROSS COUNTRY HEALTHCARE INC (CCRN) has a profitability rating of 2 / 10.
What is the valuation of CROSS COUNTRY HEALTHCARE INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CROSS COUNTRY HEALTHCARE INC (CCRN) is 508.5 and the Price/Book (PB) ratio is 1.01.
Can you provide the financial health for CCRN stock?
The financial health rating of CROSS COUNTRY HEALTHCARE INC (CCRN) is 9 / 10.